Patents/Assignees

Sarepta Therapeutics, Inc.

20 patents in portfolio

US12618850utility2026
Methods for Analyzing AAV Capsid Proteins
0 cites
US12611436utility2026
AAV Transfer Cassette
0 cites
US12577540utility2026
Suspension Mode Seed Train Development for Adherent Cells
0 cites
US12391745utility2025
Adeno-associated Virus Antibodies and Fragments Thereof
0 cites
US12377150utility2025
Exon Skipping Oligomer Conjugates for Muscular Dystrophy
0 cites
US12297219utility2025
Phosphorodiamidate Morpholino Oligomers
0 cites
US12286630utility2025
Treatment Methods for Muscular Dystrophy
0 cites
US12258362utility2025
Processes for Preparing Phosphorodiamidate Morpholino Oligomers
0 cites
US12239715utility2025
Peptide Oligonucleotide Conjugates
0 cites
US12139709utility2024
Antisense Oligomers and Methods of Using the Same for Treating Diseases Associated with the Acid Alpha-glucosidase Gene
0 cites
US12121532utility2024
Modified Antisense Oligomers for Exon Inclusion in Spinal Muscular Atrophy
0 cites
US12104163utility2024
Adeno-associated Virus Vectors for Treatment of Rett Syndrome
0 cites
US11932851utility2024
Exon Skipping Compositions for Treating Muscular Dystrophy
0 cites
US11925675utility2024
Systemic Delivery of Adeno-associated Virus Vector Expressing Gamma-sarcoglycan and the Treatment of Muscular Dystrophy
0 cites
US11911403utility2024
Antisense-induced Exon Exclusion in Type VII Collagen
0 cites
US11732259utility2023
Peptide Oligonucleotide Conjugates
0 cites
US11672871utility2023
Peptide Oligonucleotide Conjugates
0 cites
US11674139utility2023
Oligonucleotides for Treating Expanded Repeat Diseases
0 cites
US11642364utility2023
Exon Skipping Oligomer Conjugates for Muscular Dystrophy
0 cites
US11555189utility2023
Antisense Oligomer Compounds
0 cites